INOC-001

Women experiencing later menopause face an increased risk of developing asthma, contrary to previous research suggesting early menopause carries greater health risks.

Aspire Biopharma Holdings successfully completed its business combination with PowerUp Acquisition Corp., securing Nasdaq listing under ticker symbol "ASBP" effective February 20, 2025.

HRA Pharma has submitted an application to the FDA for the first over-the-counter birth control pill in the U.S., marking a significant moment in reproductive health. The application, which could lead to a decision by mid-2023, is based on years of research demonstrating the safety and effectiveness of self-screening for risks. This move could set a precedent for making contraceptives more accessible, especially to underserved populations.

A recent study suggests active monitoring may be a safe alternative to standard treatment for low-risk ductal carcinoma in situ (DCIS).

Camrelizumab plus chemotherapy significantly improved pathologic complete response (pCR) rates in early or locally advanced triple-negative breast cancer (TNBC).